MedPath

Gruppo Italiano Malattie EMatologiche dell'Adulto

🇮🇹Italy
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

127

Active:6
Completed:54

Trial Phases

5 Phases

Phase 1:4
Phase 2:45
Phase 3:9
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (72 trials with phase data)• Click on a phase to view related trials

Phase 2
45 (62.5%)
Not Applicable
13 (18.1%)
Phase 3
9 (12.5%)
Phase 1
4 (5.6%)
Phase 4
1 (1.4%)

Identification of BCR::ABL1 Mutations by Digital PCR in CML

Not Applicable
Not yet recruiting
Conditions
Chronic Myeloid Leukemia (CML)
First Posted Date
2025-09-05
Last Posted Date
2025-09-05
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
150
Registration Number
NCT07158294

Observational Study on APL-like aCute Myeloid Leukemia: disTInct Phenotype and Early VAscular complicaTions

Not yet recruiting
Conditions
Acute Myeloid Leukemia
NPM1 Mutation
First Posted Date
2025-07-23
Last Posted Date
2025-07-23
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
220
Registration Number
NCT07080970

Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM Patients

Recruiting
Conditions
Multiple Myeloma
First Posted Date
2025-04-18
Last Posted Date
2025-09-10
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
159
Registration Number
NCT06933277
Locations
🇮🇹

Aou Careggi - Sod Ematologia, Florence, Italy

Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma

Phase 2
Not yet recruiting
Conditions
Multiple Myleoma
Multiple Myeloma in Relapse
Multiple Myeloma Refractory
Interventions
First Posted Date
2025-03-25
Last Posted Date
2025-04-03
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
52
Registration Number
NCT06880601

Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia

Phase 2
Not yet recruiting
Conditions
Acute Myeloid Leukemia
FLT3 Gene Mutation
Adult AML
Diagnosis
Interventions
First Posted Date
2024-10-31
Last Posted Date
2025-03-12
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
80
Registration Number
NCT06667973
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 26
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.